secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-09-23T12:00:14+00:00
Accession:  0001683168-26-007300
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio appoints Dean Zikria as Interim CEO; board leadership reshuffled
---------------------------------------------------------------------------

- Dean Zikria appointed Interim CEO effective Sept 22, 2026; he remains on the Board.
- Zikria earns $23,333/month, 50k RSUs (plus 50k more if plan enlarged), and potential cash bonus on strategic transaction.
- Sheryle Bolton resigned from Board Sept 17, 2026; Thomas Jensen named Board Chair and Compensation Committee Chair.
- Jared Malbin appointed Audit and Risk Committee Chair; Zikria removed from audit, comp, and governance committees.
- Company emphasizes advancing Entolimod and evaluating strategic, commercial, and government opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007300/0001683168-26-007300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007300/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer